Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes

@article{Watson2013UrotensinIR,
  title={Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes},
  author={Anna M. D. Watson and Murat Olukman and Christine Koulis and Yifan Tu and Dian Samijono and Don S. H. Yuen and C. Lee and David J. Behm and Mark Emmanuel Cooper and Karin Jandeleit-Dahm and Anna C. Calkin and Terri Jean Allen},
  journal={Diabetologia},
  year={2013},
  volume={56},
  pages={1155-1165}
}
The small, highly conserved vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis have not been assessed. Endothelial cells were grown in normal- and high-glucose (5 and 25 mmol/l) media with and without UII (10−8 mol/l) and/or the UII receptor antagonist, SB-657510 (10−8 mol/l). Apoe knockout (KO) mice with or without streptozotocin-induced diabetes were treated with or without SB-657510 (30 mg kg−1 day−1; n = 20… CONTINUE READING